Business
Mirum Pharmaceuticals Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Late-breaker oral presentation features long-term data from Phase 2 ITCH and IMAGINE II studies evaluating maralixibat in pediatric patients with Alagille
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nLate-breaker oral presentation features long-term data from Phase 2 ITCH and IMAGINE II studies evaluating maralixibat in pediatric patients with Alagille syndrome\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases today announced that new data from the company’s maralixibat and volixibat studies will be presented at The Liver Meeting Digital Experience™, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 13-16, 2020.\n\nLate-breaker Oral Presentation\n\nL05: Preliminary Analysis of ITCH and IMAGINE II – Outcome of long-term administration of maralixibat in children with Alagille syndrome\n\n\nPresented by Benjamin Shneider, M.D. on November 15, 2020 during the 5:30-7:00 p.m. ET session.\n\n\nPoster Presentations\n\nAbstract #1221: A Phase 1 dose-ranging study assessing fecal bile acid excretion by volixibat, an apical sodium-dependent bile acid transporter inhibitor, and coadministration with loperamide\n\nAbstract #341: Pruritus intensity is associated with cholestasis biomarkers and quality of life measures after maralixibat treatment in children with Alagille syndrome\n\nAbstract #1792: Natural variability of pruritus in Alagille syndrome; an analysis from the ICONIC study utilizing the Itch Reported Outcome Observer (ItchRO[Obs]) tool\n\nAll posters will be available at the start of the congress on November 13, 2020 and available throughout the duration of the meeting. Abstracts are available via Hepatology on the AASLD website.\n\nAbout Maralixibat\n\nMaralixibat is a novel, minimally absorbed, orally administered investigational drug being evaluated in several rare cholestatic liver diseases. Maralixibat inhibits the apical sodium dependent bile acid transporter (ASBT), resulting in more bile acids being excreted in the feces, leading to lower levels of bile acids systemically, thereby potentially reducing bile acid mediated liver damage and related effects and complications. More than 1,600 individuals have received maralixibat, including more than 120 children who have received maralixibat as an investigational treatment for Alagille syndrome (ALGS) and progressive familial intrahepatic cholest...